Thrombin contributes to protective immunity in pneumonia-derived sepsis via fibrin polymerization and platelet–neutrophil interactions

Journal of Thrombosis and Haemostasis

Volumn 15, Issue 4, 2017, Pages 744-757

  Claushuis, T A M ^a   de Stoppelaar, S F ^a   Stroo, I ^a,b   Roelofs, J J T H ^a   Ottenhoff, R ^a   van der Poll, T ^a   van't Veer C ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b SANQUIN RESEARCH   (Netherlands)

Author keywords

blood platelets; dabigatran; fibrin; infection; sepsis; thrombin

Indexed keywords

FIBRIN; THROMBIN; DABIGATRAN; FIBRINOGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GROWTH; CELL ACTIVATION; CELL INTERACTION; COMPLEX FORMATION; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; FIBRIN POLYMERIZATION; GRAM NEGATIVE SEPSIS; HUMAN; HUMAN CELL; INHIBITION KINETICS; KLEBSIELLA PNEUMONIAE INFECTION; MOUSE; NEUTROPHIL; NONHUMAN; ORGAN INJURY; PNEUMONIA; PROTEIN DEPLETION; PROTEIN FUNCTION; SURVIVAL RATE; THROMBOCYTE; THROMBOCYTOPENIA; ANIMAL; BACTERIAL PNEUMONIA; BLOOD CLOTTING; C57BL MOUSE; CELL COMMUNICATION; CHEMISTRY; CYTOLOGY; EXTRACELLULAR TRAP; FLOW CYTOMETRY; IMMUNE SYSTEM; IMMUNOLOGY; INNATE IMMUNITY; KLEBSIELLA INFECTION; KLEBSIELLA PNEUMONIAE; LUNG; MICROBIOLOGY; MICROCIRCULATION; PATHOLOGY; SEPSIS;

ANIMALS; BLOOD COAGULATION; BLOOD PLATELETS; CELL COMMUNICATION; DABIGATRAN; EXTRACELLULAR TRAPS; FEMALE; FIBRIN; FIBRINOGEN; FLOW CYTOMETRY; HUMANS; IMMUNE SYSTEM; IMMUNITY, INNATE; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; LUNG; MICE; MICE, INBRED C57BL; MICROCIRCULATION; NEUTROPHILS; PNEUMONIA, BACTERIAL; SEPSIS; THROMBIN;

EID: 85013278353     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13625     Document Type: Article

References (48)

1. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med 2013; 369: 840–51.
2. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 2013; 13: 34–45.
3. Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med 2010; 38: S26–34.
4. Levi M, van der Poll T, Schultz M. Systemic versus localized coagulation activation contributing to organ failure in critically ill patients. Semin Immunopathol 2012; 34: 167–79.
5. Niessen F, Schaffner F, Furlan-Freguia C, Pawlinski R, Bhattacharjee G, Chun J, Derian CK, Andrade-Gordon P, Rosen H, Ruf W. Dendritic cell PAR1-S1P3 signalling couples coagulation and inflammation. Nature 2008; 452: 654–8.
6. Kager LM, Wiersinga WJ, Roelofs JJ, van‘t Veer C, van der Poll T. Deficiency of protease-activated receptor-1 limits bacterial dissemination during severe Gram-negative sepsis (melioidosis). Microbes Infect 2014; 16: 171–4.
7. Warr TA, Mohan Rao LV, Rapaport SI. Disseminated intravascular coagulation in rabbits induced by administration of endotoxin or tissue factor: effect of anti-tissue factor antibodies and measurement of plasma extrinsic pathway inhibitor activity. Blood 1990; 75: 1481–9.
8. Van Den Boogaard FE, Brands X, Schultz MJ, Levi M, Roelofs JJ, van‘t Veer C, van der Poll T. Recombinant human tissue factor pathway inhibitor exerts anticoagulant, anti-inflammatory and antimicrobial effects in murine pneumococcal pneumonia. J Thromb Haemost 2011; 9: 122–32.
9. Taylor FB Jr, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Investig 1987; 79: 918–25.
10. Minnema MC, Chang ACK, Jansen PMY, Lubbers TP, Pratt BM, Whittaker BG, Taylor FB, Hack CE, Friedman B. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood 2000; 95: 1117–23.
11. Loubele S, Ten Cate H. Local administration of recombinant human antithrombin in a mouse model of peritoneal sepsis. J Thromb Haemost 2006; 4: 2340–2.
12. Clark SR, Ma AC, Tavener SA, McDonald B, Goodarzi Z, Kelly MM, Patel KD, Chakrabarti S, McAvoy E, Sinclair GD, Keys EM, Allen-Vercoe E, Devinney R, Doig CJ, Green FH, Kubes P. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med 2007; 13: 463–9.
13. de Stoppelaar SF, van‘t Veer C, Claushuis TAM, Albersen BJA, Roelofs JJTH, van der Poll T. Thrombocytopenia impairs host defense in gram-negative pneumonia-derived sepsis in mice. Blood 2014; 124: 3781–90.
14. Massberg S, Grahl L, von Bruehl ML, Manukyan D, Pfeiler S, Goosmann C, Brinkmann V, Lorenz M, Bidzhekov K, Khandagale AB, Konrad I, Kennerknecht E, Reges K, Holdenrieder S, Braun S, Reinhardt C, Spannagl M, Preissner KT, Engelmann B. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med 2010; 16: 887–96.
15. McDonald B, Urrutia R, Yipp BG, Jenne CN, Kubes P. Intravascular neutrophil extracellular traps capture bacteria from the bloodstream during sepsis. Cell Host Microbe 2012; 12: 324–33.
16. Sun H, Wang X, Degen JL, Ginsburg D. Reduced thrombin generation increases host susceptibility to group A streptococcal infection. Blood 2009; 113: 1358–64.
17. Bhattacharya S, Ploplis VA, Castellino FJ. Bacterial plasminogen receptors utilize host plasminogen system for effective invasion and dissemination. J Biomed Biotechnol 2012; 2012: 482096.
18. de Stoppelaar SF, van't Veer C, van den Boogaard FE, Nieuwland R, Hoogendijk AJ, de Boer OJ, Roelofs JJ, van der Poll T. Protease activated receptor 4 limits bacterial growth and lung pathology during late stage Streptococcus pneumoniae induced pneumonia in mice. Thromb Haemost 2013; 110: 582–92.
19. Mosesson MW. Thrombin interactions with fibrinogen and fibrin. Semin Thromb Hemost 1993; 19: 361–7.
20. Sambrano GR, Weiss EJ, Zheng Y-W, Huang W, Coughlin SR. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature 2001; 413: 74–8.
21. Siller-Matula JM, Schwameis M, Blann A, Mannhalter C, Jilma B. Thrombin as a multi-functional enzyme. Focus on in vitro and in vivo effects. Thromb Haemost 2011; 106: 1020–33.
22. Szaba FM, Smiley ST. Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood 2002; 99: 1053–9.
23. Ma L, Dorling A. The roles of thrombin and protease-activated receptors in inflammation. Semin Immunopathol 2012; 34: 63–72.
24. Shankar R, de la Motte CA, Poptic EJ, DiCorleto PE. Thrombin receptor activating peptides differentially stimulate platelet derived growth factor production, monocytic cell adhesion, and E-selectin expression in human umbilical vein endothelial cells. J Biol Chem 1994; 269: 13936–41.
25. Kaplan ZS, Zarpellon A, Alwis I, Yuan Y, McFadyen J, Ghasemzadeh M, Schoenwaelder SM, Ruggeri ZM, Jackson SP. Thrombin-dependent intravascular leukocyte trafficking regulated by fibrin and the platelet receptors GPIb and PAR4. Nat Commun 2015; 6: 7835.
26. Schouten M, Wiersinga WJ, Levi M, van der Poll T. Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol 2008; 83: 536–45.
27. Kang CI, Song JH, Chung DR, Peck KR, Ko KS, Yeom JS, Ki HK, Son JS, Lee SS, Kim YS, Jung SI, Kim SW, Chang HH, Ryu SY, Kwon KT, Lee H, Moon C, Korean Network for Study of Infectious Diseases (KONSID). Risk factors and pathogenic significance of severe sepsis and septic shock in 2286 patients with gram-negative bacteremia. J Infect 2011; 62: 26–33.
28. Sparkenbaugh EM, Chantrathammachart P, Mickelson J, van Ryn J, Hebbel RP, Monroe DM, Mackman N, Key NS, Pawlinski R. Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease. Blood 2014; 123: 1747–56.
29. de Boer JD, Berkhout LC, de Stoppelaar SF, Yang J, Ottenhoff R, Meijers JC, Roelofs JJ, van't Veer C, van der Poll T. Effect of the oral thrombin inhibitor dabigatran on allergic lung inflammation induced by repeated house dust mite administration in mice. Am J Physiol Lung Cell Mol Physiol 2015; 309: L768–75.
30. Brill A, Fuchs TA, Savchenko AS, Thomas GM, Martinod K, De Meyer SF, Bhandari AA, Wagner DD. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost 2012; 10: 136–44.
31. Rijneveld AW, Weijer S, Bresser P, Florquin S, Vlasuk GP, Rote WE, Spek CA, Reitsma PH, van der Zee JS, Levi M, van der Poll T. Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia. Crit Care Med 2006; 34: 1725–30.
32. Jose RJ, Williams AE, Mercer PF, Sulikowski MG, Brown JS, Chambers RC. Regulation of neutrophilic inflammation by proteinase-activated receptor 1 during bacterial pulmonary infection. J Immunol 2015; 194: 6024–34.
33. Martinod k, Fuchs TA, Zitomersky NL, Wong SL, Demers M, Gallant M, Wang Y, Wagner DD. PAD4-deficiency does not affect bacteremia in polymicrobial sepsis and ameliorates endotoxemic shock. Blood 2015; 25: 1948–56.
34. Li P, Li M, Lindberg MR, Kennett MJ, Xiong N, Wang Y. PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps. J Exp Med 2010; 207: 1853–62.
35. Rydel TJ, Ravichandran KG, Tulinsky A, Bode W, Huber R, Roitsch C, Fenton JW. The structure of a complex of recombinant hirudin and human alpha-thrombin. Science 1990; 249: 277–80.
36. Laudano AP, Doolittle RF. Studies on synthetic peptides that bind to fibrinogen and prevent fibrin polymerization. Structural requirements, number of binding sites, and species differences. Biochemistry 1980; 19: 1013–9.
37. Chackalamannil S, Wang Y, Greenlee WJ, Hu Z, Xia Y, Ahn HS, Boykow G, Hsieh Y, Palamanda J, Agans-Fantuzzi J, Kurowski S, Graziano M, Chintala M. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem 2008; 51: 3061.
38. de Stoppelaar SF, van't Veer C, Roelofs JJ, Claushuis TA, de Boer OJ, Tanck MW, Hoogendijk AJ, van der Poll T. Platelet and endothelial cell P-selectin are required for host defense against Klebsiella pneumoniae-induced pneumosepsis. J Thromb Haemost 2015; 13: 1128–38.
39. Opal SM, van der Poll T. Endothelial barrier dysfunction in septic shock. J Intern Med 2015; 277: 277–93.
40. Alshehri OM, Hughes CE, Montague S, Watson SK, Frampton J, Bender M, Watson SP. Fibrin activates GPVI in human and mouse platelets. Blood 2015; 26: 1601–8.
41. Neumann FJ, Marx N, Gawaz M, Brand K, Ott I, Rokitta C, Sticherling C, Meinl C, May A, Schomig A. Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets. Circulation 1997; 95: 2387–94.
42. Prasad JM, Gorkun OV, Raghu H, Thornton S, Mullins ES, Palumbo JS, Ko YP, Hook M, David T, Coughlin SR, Degen JL, Flick MJ. Mice expressing a mutant form of fibrinogen that cannot support fibrin formation exhibit compromised antimicrobial host defense. Blood 2015; 126: 2047–58.
43. McAdow M, Kim HK, Dedent AC, Hendrickx AP, Schneewind O, Missiakas DM. Preventing Staphylococcus aureus sepsis through the inhibition of its agglutination in blood. PLoS Pathog 2011; 7: e1002307.
44. Flick MJ, Du X, Prasad JM, Raghu H, Palumbo JS, Smeds E, Hook M, Degen JL. Genetic elimination of the binding motif on fibrinogen for the S. aureus virulence factor ClfA improves host survival in septicemia. Blood 2013; 121: 1783–94.
45. Vanassche T, Kauskot A, Verhaegen J, Peetermans WE, van Ryn J, Schneewind O, Hoylaerts MF, Verhamme P. Fibrin formation by staphylothrombin facilitates Staphylococcus aureus-induced platelet aggregation. Thromb Haemost 2012; 107: 1107–21.
46. Vanassche T, Verhaegen J, Peetermans WE, van Ryn J, Cheng A, Schneewind O, Hoylaerts MF, Verhamme P. Inhibition of staphylothrombin by dabigatran reduces Staphylococcus aureus virulence. J Thromb Haemost 2011; 9: 2436–46.
47. Jaimes F, De La Rosa G, Morales C, Fortich F, Arango C, Aguirre D, Munoz A. Unfractioned heparin for treatment of sepsis: a randomized clinical trial (The HETRASE Study). Crit Care Med 2009; 37: 1185–96.
48. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Pénzes I, Kübler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM, KyberSept Trial Study Group. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001; 286: 1869–78.